ArticleBMC microbiology2025
Characterization and genome analysis of jumbo Escherichia phage UE-S1 and the antibacterial potential of its lysozyme against uropathogenic E. coli.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genomic and functional characterization ofFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEvery year, millions of individuals worldwide are affected by urinary tract infections (UTIs), one of the most frequent bacterial infections. Uropathogenic Escherichia coli strains (UPEC) are the main cause of both complicated and uncomplicated UTIs. In addition, uropathogens are becoming progressively more resistant to commonly prescribed antibiotics. As a result, new strategies for the prevention and treatment of UTIs must be developed, and the use of bacteriophages and their enzymes are potential options to eliminate uropathogens from the urinary tract.
resultsThe present study aimed to investigate the therapeutic efficiency of a UE-S1 phage and its lysozyme (LysUE1) against the MDR UPEC strain PSU-5266 (UE-17). The phage UE-S1 was isolated from sewage water and exhibited potent lytic activity against the UPEC strain. Biological characterization revealed that phage UE-S1 was stable over a wide range of temperatures (4 °C to 55 °C) and pH values (3 to 11) with an adsorption time of 15 min. The phage was able to lyse 31% (27/86) of the assessed bacterial strains and significantly inhibited bacterial growth without inducing phage resistance. TEM micrographs revealed that the phage had a Myoviridae morphology with an icosahedral head and long contractile tail. The genomic analysis of phage UE-S1 revealed that it is a jumbo phage with a 358 kb genome encoding 595 putative open reading frames. Among these, 108 predicted genes with putative functions were primarily associated with nucleotide metabolism, DNA replication, and recombination. Additionally, no antibiotic resistance, virulence, or lysogenic genes were detected. Phylogenetic analysis revealed that the new phage UE-S1 belongs to the genus Asteriusvirus. Moreover, the phage lysozyme LysUE1 was cloned, expressed, and purified. LysUE1 demonstrated lytic activity against Gram-negative (pathogenic E. coli strains) and Gram-positive (S. aureus) strains.
conclusionOverall, the results indicated that phage UE-S1 and its lysozyme LysUE1 might be promising therapeutic agents for combating multidrug-resistant UPEC in UTIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.